ACB - Aurora Cannabis Inc.

NYSE - NYSE Delayed Price. Currency in USD
-0.21 (-2.36%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close8.89
Bid8.61 x 40700
Ask8.65 x 21500
Day's Range8.65 - 9.05
52 Week Range4.05 - 12.52
Avg. Volume28,097,911
Market Cap8.918B
Beta (3Y Monthly)2.62
PE Ratio (TTM)40.19
EPS (TTM)0.22
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • 3 Brand-Name Food and Beverage Companies That Want In on the Marijuana Craze
    Motley Fool14 hours ago

    3 Brand-Name Food and Beverage Companies That Want In on the Marijuana Craze

    Edibles and infused beverages have these well-known snack and beverage businesses seeing green.

  • Better Buy: Aphria vs. Aurora Cannabis
    Motley Fool15 hours ago

    Better Buy: Aphria vs. Aurora Cannabis

    One of these marijuana stocks has been the bigger winner recently. But which is better poised to win in the future?

  • Where Aurora sees cannabis opportunity beyond selling buds in Canada
    MarketWatch17 hours ago

    Where Aurora sees cannabis opportunity beyond selling buds in Canada

    As recreational marijuana moves beyond buds and countries besides Canada mull legalization, cannabis companies have a lot of potential roads to travel as they seek to grow.

  • Aurora maps its future as New Jersey gets set to put cannabis legalization to the vote
    MarketWatch17 hours ago

    Aurora maps its future as New Jersey gets set to put cannabis legalization to the vote

    Aurora Cannabis Inc. shares were in focus again Thursday, as investors continued to digest weaker-than-expected earnings and the company’s plans to grow its business.

  • You'll Never Guess Who's Betting Against Canadian Cannabis Stocks
    Motley Fool17 hours ago

    You'll Never Guess Who's Betting Against Canadian Cannabis Stocks

    The chairman of a giant U.S. cannabis company wants to use a controversial investing strategy.

  • The Cannabis Craze

    The Cannabis Craze

    The "Cannabis Craze" had everyone and their brother buying up marijuana stocks. These cannabis stocks didn't have enough free-floating shares to cover the massive amount of buy interest leading them to skyrocketed at the end of 2018 far above their fair value.

  • There’s an Opportunity Brewing in Aurora Cannabis (ACB) Stock, Says Analyst
    SmarterAnalyst18 days ago

    There’s an Opportunity Brewing in Aurora Cannabis (ACB) Stock, Says Analyst

    So you want to invest in a marijuana stock, but you don't know which one to pick?That's not an uncommon dilemma for investors today, says Desjardins analyst John Chu. Attempting to get a handle on the various players in this market, "investors continue to struggle with valuation metrics and market size estimates that seem to be increasing every week."So what's the solution? In Chu's case, it is to create a "scorecard [that] captures a company’s current operational footprint, its brand and distribution as well as future growth prospects" and to "use this scorecard to help determine our valuation multiple and discount rate relative to its peers."Granted, even that isn't as simple as it sounds. With most cannabis companies being expected to lose money this year, figuring out how to hang a valuation on these stocks can be tricky. Chu's solution is to guesstimate how a particular company might look five years from now, by which point the analyst believes the industry will have settled down from its current revenue hypergrowth-slash-nonexistent profits stage, and most companies can be expected to earn profits "in the high-teens or low-20% range" as a percentage of revenue.And that's what Chu has done for Aurora Cannabis (ACB).Chu values Aurora stock at a current enterprise value of 22 times its expected earnings before interest, taxes, depreciation, and amortization (EBITDA) in 2023. That may sound like a lot to pay for earnings that won't materialize for another five years. Nevertheless, Chu thinks it's a relatively safe bet (with only "average" risk), and assigns Aurora stock a "buy" rating and a price target of C$16.50, which implies nearly 35% upside from current levels. (To watch Chu's track record, click here)Running Aurora through a battery of tests, evaluating its strengths (and weaknesses) in 24 separate categories, and assigning a score of from 0 to 5 points each, Chu assigns Aurora Cannabis a score of 89 out of 120 total possible points. In Chu's estimation, Aurora scores highest (4 or 5 points each) in the categories of scale of operations, medical marijuana, technology, management, product awards, innovation, clinical trials, positioning in the hemp and international markets, presence in pharmacies and clinics, having Canadian provincial supply agreements in hand, and being "Good Manufacturing Compliant" (GMP) under EU standards.But it's Aurora's position in medical marijuana that most impresses this analyst. In recreational marijuana, Aurora "is no slouch" with a 13% share of the Canadian market, second only to Canopy Growth (CGC). But "Aurora Cannabis is uniquely positioned to dominate the domestic medical market and, in turn, the international medical market," says Chu.Aurora is in the process of building out "the largest production footprint in Canada" -- as much as 600,000 kilograms of marijuana production annually, and its operations are more automated than any of its rivals, resulting in as much as 30% additional yield per square foot relative to the competition's floor space.Not only does this mean Aurora grows more weed than anybody else. That extra scale of operation, argues the analyst, allows Aurora to grow marijuana more efficiently, such that once it reaches its full potential, Aurora should be able to cut its cost of production to less than C$1 per gram.To read more on the nitty gritty of what’s going on in the rising cannabis industry, click here. Read more on ACB: * Cowen Counts the Points in Aurora Cannabis (ACB) Stock’s Favor * How Aurora Cannabis (ACB) Stock Gets to $11 * Aurora Cannabis (ACB) Stock Is in Position for Another Bullish Leg More recent articles from Smarter Analyst: * Gene Munster: Key Takeaways From Nvidia (NVDA) Earnings * Trade War? Top Analyst Says Alibaba (BABA) Stock Still a Buy * The Green Organic Dutchman (TGODF) Stock -- Not Sinking Exactly, But Not Sailing Anywhere Fast * Is Boeing (BA) Stock a Buy Ahead of FAA Announcement?

  • The Cannabis ‘Magic Bus’ Is About to Depart the Station! Next Stops? Aurora Cannabis, Hexo, Canopy Growth and Aphria
    SmarterAnalyst8 days ago

    The Cannabis ‘Magic Bus’ Is About to Depart the Station! Next Stops? Aurora Cannabis, Hexo, Canopy Growth and Aphria

    Now here's something you don't see every day.Up in Canada, investment banker Seaport Global just announced a first of its kind offer to cart its investor clients around Canada aboard a "magic bus" -- they didn't call it that, so we will -- as part of a tour of cannabis production facilities operated by Canadian marijuana companies Aurora Cannabis (ACB), Hexo (HEXO), Canopy Growth (CGC), and Aphria (APHA).("Paging Willie Nelson. Your bus is about to depart the station.")Seaport's "inaugural get on the Bus tour" will depart Quebec on June 3 and continue cross country to Ontario, eventually ending on June 4, and provide investors a chance to quiz management teams on such fascinating subjects as "about forward capital allocation, potential market oversupply, global expansion plans, anticipated product/market development, and strategies for the US market."No word on whether refreshments will be provided.That's the headline news -- but seeing as this offer is limited to folks who know an "SGS salesperson" or "analyst team" to contact, it would appear that space on this magic bus will be limited to very well-heeled Seaport Global clientele. As for the rest of us, the great unwashed of marijuana investing, we may find more of interest in Seaport's executive summary of the state of the marijuana market that Seaport and its clients will be delving into next month.To wit, Seaport's Brett Hundley notes that right now, the Canadian cannabis market is worth about $1 billion, with demand for about 600,000 kilograms of marijuana (in all its forms) per year. (Which works out to one kilogram of generic pot product costing about $1,700 -- or about a buck-seventy per gram).Hundley sees this market growing about 10 times in size "over time," to $10 billion in annual sales, with eventual demand by weight equaling 5.5 million kg. (Or put another way, $1,800 per kilo, or a buck-eighty per gram).Now, we can see the economics students in class waving their arms and objecting that this doesn't sound right -- that as the marijuana market matures and supply of legal pot explodes, demand should go up and prices should come down. And we agree with you -- but this is Hundley's show. Hundley may also be factoring inflation into the picture, in which case, it's entirely possible that $1.80 a gram seven years from now will be a cheaper price than $1.60 a gram is today.Other points related by the analyst in his write-up, which may be of interest to investors lacking tickets to ride the magic bus: Hundley notes that currently, Canadian pot companies are producing pot at the rate of about 725,000 kg per annum -- which means more than 20% oversupply for a market that's currently only demanding 600,000 kg a year. The analyst thinks that over time, this oversupply will moderate. However, he also notes that producers plan to eventually produce more than 6 million kg of pot per year -- which is also more than Hundley estimated end-market demand of 5.5 million kg, seven years from now.Long story short: Marijuana is in oversupply right now, and could very well remain so in the future. Cannabis investors would like to snag a seat on Seaport's magic bus, and ask Aurora, Hexo, Canopy, and Aphria how they plan to rectify this situation.Good luck with that.To read more on the nitty gritty of what’s going on in the rising cannabis industry, click here. Read more on the stocks mentioned: * Analyst Sees Some Challenges in Aurora Cannabis (ACB) Stock * Hexo: The Cheapest Way to Invest in a Giant Market for Marijuana? * Is This Breakout the Time to Be Buying Canopy Growth (CGC) Stock? * Aphria (APHA): Growing Pains in the Cannabis Industry More recent articles from Smarter Analyst: * Gene Munster: Key Takeaways From Nvidia (NVDA) Earnings * Trade War? Top Analyst Says Alibaba (BABA) Stock Still a Buy * Why Cannabis Stock HEXO Has a Bright Future * The Green Organic Dutchman (TGODF) Stock -- Not Sinking Exactly, But Not Sailing Anywhere Fast

  • Are These Marijuana Stocks A Good Buy Now? Look Past The Hype
    Investor's Business Dailyyesterday

    Are These Marijuana Stocks A Good Buy Now? Look Past The Hype

    Are marijuana stocks on U.S. exchanges a good buy now? The marijuana industry gets a lot of hype, but look past the smoke and analyze pot stocks on their fundamentals and technicals.

  • Without a Better Story, Cronos Stock May Have Further to Fall
    InvestorPlace2 days ago

    Without a Better Story, Cronos Stock May Have Further to Fall

    Marijuana stocks like Cronos (NASDAQ:CRON) look a bit creaky at the moment, and CRON stock may be Exhibit A in the case that the group is stalling out. Cronos stock has dropped by over one-third just since early March, with the near-term question whether a recent bottom can hold.Source: Shutterstock I'm skeptical it will. Valuation is a bit more reasonable than it was earlier this year, when I thought Cronos Group stock was overvalued. But CRON is hardly cheap. Analysts have turned bearish. And that bearishness seems to coincide with the core problem here.Cronos simply hasn't driven the right kind of narrative for a marijuana stock at this valuation. Looking around the sector, there are concise, obvious bull cases for most of the well-covered stocks. Outside of the nearly $2 billion in cash coming in from Altria (NYSE:MO), Cronos lacks that case. And until that changes, Cronos is likely to struggle.InvestorPlace - Stock Market News, Stock Advice & Trading Tips * 6 Chinese Stocks That Could Pop On a Trade Deal The Need for a StoryInvesting in cannabis stocks at the moment isn't about the fundamentals. This is an industry at the very beginning of its growth. Price/earnings and even price/sales multiples are enormous and not necessarily comparable. The fundamental toolkit an investor might use to value a mature company simply doesn't apply in the sector at the moment.And so both the decision to invest in the sector at all, and which cannabis stock to choose, come down largely to long-term projections and even feel. Will the industry grow for years, as proponents argue? Is the oversupply already seen in legalized U.S. markets like Oregon a long-term risk? When does broader U.S. legalization arrive? Who of the myriad publicly traded cannabis plays wins and who loses?In that type of investing environment, a stock needs a succinct bull case, an elevator pitch so to speak. And most of the well-covered cannabis plays have that type of case. Canopy Growth (NYSE:CGC) is the early leader, and thanks to Constellation Brands (NYSE:STZ,NYSE:STZ.B) has the largest war chest. Aurora Cannabis (NYSE:ACB) is taking so many shots on goal that it's likely to score on at least one of them. Charlotte's Web (OTCMKTS:CWBHF) is the pure play on CBD (cannabidiol) oil. Even struggling Tilray (NASDAQ:TLRY) may have positioned itself to win if capacity gets overbuilt. And so on. What Is the Story Behind CRON Stock?What's the story behind CRON stock, however? The company has a ton of cash coming in, to be sure. But its production capabilities aren't particularly impressive: as The Motley Fool noted, Cronos isn't even in the top ten in terms of available capacity. Its Spinach retail brand doesn't appear as strong as those from Canopy or Hexo (NYSE:HEXO). Its positioning in the Canadian adult-use market seems behind that of many peers.Even analysts somewhat favorable to the stock aren't sure what to make of it, as James Brumley noted earlier this month. CIBC World Markets analyst John Zamparo wrote that the company hadn't given much colors on its plans for actually using that capital. Cannacord Genuity cited "a number of strategic initiatives that could eventually unlock longer-term value."Those aren't compelling points in favor of Cronos stock. Rather, they're something more akin to a "poke and hope" strategy. Cronos has a lot of cash, and the marijuana industry should grow, so the company will eventually figure something out. That kind of case might work in the middle of 2018, or the beginning of 2019, when marijuana stocks on the whole are soaring. As we've seen of late, however, it can't work forever. Cronos Group Stock Isn't CheapMeanwhile, Cronos remains priced in line with those peers who have better stories - and better growth. Cronos' Q1 report wasn't particularly impressive either fundamentally or in terms of management commentary. The company did turn a profit but only thanks to non-cash benefits, some of which related to the Altria deal. On an operating basis, Cronos continues to lose money.That's not a problem on its own: most stocks in the space are posting operating losses as they build out production, processing, and supply chain capabilities. But CRON, relative to revenue, continues to be valued roughly in line with the leaders of the space.That's not going to hold if Cronos can't prove that it will be a leader long-term. Right now, it's not making a good enough case - and until that changes, Cronos stock is going to underperform. And with marijuana stocks right now seeming to stall out, that in turn suggests that CRON is headed below $15.As of this writing, Vince Martin has no positions in any securities mentioned. More From InvestorPlace * 4 Top American Penny Pot Stocks (Buy Before June 21) * 7 Stocks to Buy that Lost 10% Last Week * Top 7 Dow Jones Stocks of 2019 -- So Far * 5 Service Stocks That Can Win the Trade War -- According to Goldman Sachs Compare Brokers The post Without a Better Story, Cronos Stock May Have Further to Fall appeared first on InvestorPlace.

  • How Trade War 2.0 Benefits Struggling Cronos Stock
    InvestorPlace2 days ago

    How Trade War 2.0 Benefits Struggling Cronos Stock

    As things stand now, cannabis firm Cronos Group (NASDAQ:CRON) is a two-faced investment. CRON stock recovered well from late last year's volatility, as CRON stock is up nearly 49% since the beginning of January. But Cronos stock shed 30% since March 1, putting a sour taste in recent buyers' mouths.Source: Shutterstock Fundamentally, Cronos has the same split personality. Last week, the company reported its first-quarter results. On paper, Cronos delivered a strong beat. Analysts' consensus estimate pegged earnings per share at a loss of two cents. Instead, EPS came in at 36 cents on the positive end of the scale.Moreover, Cronos rang up 6.47 million CAD, or $4.8 million, of net sales. That was a massive 120% increase from the year-ago quarter. But as The Motley Fool's Sean Williams noted, the cannabis firm benefited from multiple one-off events. All things considered Cronos Group loses money on its operations.InvestorPlace - Stock Market News, Stock Advice & Trading TipsInvestorPlace Managing Editor John Kilhefner has also joined in on the fun. Kilhefner bought CRON stock because, in his words, he was "greedy." He wanted a "quick short-term boost" and what better place to get that than with marijuana? * 6 Chinese Stocks That Could Pop On a Trade Deal However, Kilhefner now regrets buying Cronos stock. For one thing, after clearing his thoughts, he doesn't view marijuana as an investment but rather, pure speculation. More critically, the reality of cannabis hasn't come anywhere close to the hype. For instance, Canadian cannabis stores are selling fewer botanical products than previously anticipated.With that negative backdrop, it's no wonder why investors are have mixed views on CRON stock. Still, I think Kilhefner and others may want to consider another massive catalyst: China. CRON Stock Has Received a Massive TailwindOne of the more surprising developments in geopolitics recently is that the trade war is back on. For weeks, it appeared that the Trump administration and its Chinese counterpart were ready to make a deal.But the deal appears to have fallen through. This latest freeze in U.S.-China relations may not thaw for quite some time. As InvestorPlace's William Roth explained, our military exercises in the South China Sea appeared to have been carefully orchestrated.What does that have to do with CRON stock? Everything. Trump has pushed himself into a corner economically. The initial round of tariffs already hurt many businesses across multiple sectors. With the President threatening even harsher penalties, astute market observers are bracing themselves for a rough landing.Of course, one sector that has absorbed substantial damage is agriculture. Already weakened from demographic challenges, American farmers have been put in a vice grip by tariffs. Since much of this country's agricultural base is located in conservative regions, Trump can't play hardball with the Chinese without incurring political penalties.That is where CRON stock and other major marijuana names like Canopy Growth (NYSE:CGC) and Aurora Cannabis (NYSE:ACB) come into the picture. If this "trade war 2.0" worsens - again, Roth forwarded evidence that it will - full recreational legalization is on the table.Despite growing political momentum, getting rid of the federal government's Schedule I classification appeared to be a pipe dream. Even during the Obama administration, marijuana tip-toed a delicate balance between states' rights and federal oversight.But right now, there's a good chance that our economy will enter a recession. Trump will either have to give in to the Chinese or make concessions on the cannabis legalization front. I'd say that's a long-term benefit to CRON stock. Don't Give Up on Cronos Stock!If Kilhefner hasn't dumped his shares of Cronos Group stock, I'd recommend he bite the bullet and wait. Politically, what's currently happening is the best thing ever for the marijuana industry.If I know anything about the Chinese, they hate losing face. If I know anything about Trump, he hates losing, period. Both Trump and his counterpart, President Xi, are egomaniacs who are unwilling to concede an inch to each other.In this situation, China must rely more on its allies, Russia and North Korea. We, on the other hand, are in a great position: we don't need dictators and despots to prop up our economy. Instead, we just need to convince roughly half our citizens that they won't be condemned to eternal damnation for their botanical indulgences.While religion has been historically very strong in this country, that goes away in a recession. The easy fix is legalization, or at least a much more tolerant (and transparent) policy.I agree with Kilhefner that CRON stock is a gamble. However, I disagree with his conclusion. Now is the best time to consider making that bet.As of this writing, Josh Enomoto did not hold a position in any of the aforementioned securities. More From InvestorPlace * 4 Top American Penny Pot Stocks (Buy Before June 21) * 6 Trade War Stocks With a Lot of Risk * 7 Bond ETFs to Buy * 10 Stocks That Could Squeeze Short Sellers, Including CGC Compare Brokers The post How Trade War 2.0 Benefits Struggling Cronos Stock appeared first on InvestorPlace.

  • Benzinga2 days ago

    Large Option Traders Are Selling The Aurora Cannabis Earnings Pop

    Aurora Cannabis Inc (NYSE: ACB) shares traded higher by 8 percent this week after the company reported a mixed first-quarter earnings report Tuesday evening. Throughout the week, Benzinga Pro subscribers received a number of options alerts related to Aurora Cannabis. On Wednesday morning around 10:30 a.m., a trader sold 2,000 Aurora call options at a $9 strike price that expire on Dec. 20.

  • The Bullish Thesis for Tilray Stock Is Still Alive and Well
    InvestorPlace2 days ago

    The Bullish Thesis for Tilray Stock Is Still Alive and Well

    Every so often, Wall Street experiences a craze that is fascinating like Bitcoin in 2017. But now it's the cannabis stocks and Tilray (NASDAQ:TLRY) has been a wild one to watch. It went public last year and within two months it had rallied 1,000%. 2019 has not been kind to TLRY stock as it's down 32% year-to-date, yet it is still up 110% since its inception. Compare that to the S&P 500, which is barely up 2% in a year.Source: Shutterstock Today's write up is to encourage those who like the stock to hold it and to also discourage those who want to short it. For full disclosure, I am not long Tilray nor am I an uber fan or a perma-bull of it.While the IPO was orderly, the period that followed was bonkers. In September it spiked to its $300 all-time high from $93 in three days. Clearly, it was a massive short squeeze where buying begot buying until the equilibrium was restored.InvestorPlace - Stock Market News, Stock Advice & Trading TipsUnfortunately for the Tilray stock bulls that was the high mark and it has traded horrendously since then. It is now below $50 and it can't sustain a rally. It's not so much that the fundamentals have deteriorated greatly. It is simply that the stock trade broke from the massive artificial rally. It takes time to restore the natural price action.TLRY still has not grabbed the attention of major corporations. Canopy Growth (NYSE:CGC) and Cronos (NASDAQ:CRON) got billions from Constellation Brands (NYSE:STZ) and Altria (NYSE:MO). Tilray is still going at it alone and it's struggling. It will need better alliances or it risks falling behind.Before you send me hate mail on this, I am not calling TLRY stock dead. Cannabis stocks are a special breed in this early stage. They are trying to establish the industry on Main Street and they may not be able to always impress Wall Street in the short term. There will be ups and downs but the bullish thesis is too diverse in scope to call it dead now. * 10 Baby Boomer Stocks to Buy So what's a fair value for TLRY stock? There is none because at this point they all carry massive market capitalization but with a tiny fraction of it in sales. TLRY's cap is $6 billion and it recently reported $23 million in sales.To that, management reported a big top line beat and 195% growth year over year. The stock spiked 6% on the headline and it is holding the zone decently given the overall stock market jitters. More importantly, its deliveries doubled year-over-year and that is the focus of many experts. They can't grow into their potential if they cannot deliver it as well as improve their margins along the way.The cannabis industry is still trying to adjust to its new legal status. This is a trend that is spotty for now but will grow its ubiquity with time. The U.S. market is an important one and many states will soon follow the ones that have already legalized it. But on the federal level, it may not be that easy. Luckily there are dozens of other countries for TLRY to potentially serve. Bottom Line on TLRY StockThe hoopla around cannabis stocks like Tilray is that they will disrupt so many huge markets that their upside potential should also be massive. The recreational use is what first comes to mind to most people but there are so many more like medicinal applications, potables and edibles. Maybe one day pot-based drinks will replace some of the soda, wine and beer consumption. * Top 7 Dow Jones Stocks of 2019 -- So Far Skeptics would call it a craze. Maybe, but unlike bitcoin where the concept escapes 99% of all people, everyone knows what cannabis is and is immediately interested in learning more about it. The allure of it is undeniable as I see evidence of the interest everywhere I go.So the bottom line is that although the experts can dismiss Tilray based on valuation and its distance from its all-time high, they would be making a mistake. Because as big as the potential of this multi-headed future area of business is, it will be impossible to quantify here let alone judge it right. Either avoid it altogether or plug your nose and buy the stock for the long term.We saw the skeptics lose fortunes trying to short Amazon (NASDAQ:NFLX) and Netflix (NASDAQ:NFLX). Netflix still gets a pass on profitability because of its global expansion potential as should most cannabis stocks … including TLRY stock.Nicolas Chahine is the managing director of As of this writing, he did not hold a position in any of the aforementioned securities. You can follow him as @racernic on Twitter and Stocktwits. More From InvestorPlace * 4 Top American Penny Pot Stocks (Buy Before June 21) * 7 Stocks to Buy that Lost 10% Last Week * Top 7 Dow Jones Stocks of 2019 -- So Far * 5 Service Stocks That Can Win the Trade War -- According to Goldman Sachs Compare Brokers The post The Bullish Thesis for Tilray Stock Is Still Alive and Well appeared first on InvestorPlace.

  • Aurora Cannabis (ACB) Stock Is at the Mercy of Investors
    SmarterAnalyst2 days ago

    Aurora Cannabis (ACB) Stock Is at the Mercy of Investors

    In not a huge surprise, Aurora Cannabis (ACB) reported FQ3 numbers for the March quarter that missed analyst estimates. Also not a big surprise, the stock is flat to up on the miss. The numbers provide a crucial insight into the troubling sales of legalized cannabis in the Canadian adult-use market, but the company still has a huge market opportunity to spin the stock market back towards a positive long-term view.Looking Past Disappointing QuarterFor the quarter, Aurora reported revenues of C$65.1 million compared to estimates up at C$67.5 million. Typically, such a revenue miss would crush a company with a $9 billion market cap that is only delivering about $50 million in quarterly revenues, but a lot of the global market opportunity isn’t open yet including consumables in Canada.The market is quickly looking past the quarter despite the company reporting a large EBITDA loss of C$36.6 million. The big issue with the Canadian companies is the push for wide global expansion that has a company like Aurora spending wild on future sales that aren’t guaranteed. For this reason, SG&A expenses were C$67.1 million in the quarter; though relatively flat from the prior quarter.A couple of key figures for the quarter are the gross margin and the average net selling price. In FQ3, Aurora saw the gross margin rise slightly to 55% and the selling price per gram dipped 6% sequentially to C$6.40 per gram. The weakness here is problematic with a ton of additional supply hitting the market over the next year.Supply QuestionsThe question Aurora hasn’t really answered for investors is what happens with the additional supply hitting the market this quarter and in the future. The large cannabis company has long projected reaching an annual production rate of 150,000 kg by the end of March and still maintains 25,000 kgs on the market in the June quarter.The large cannabis company harvested 15,590 kgs in the March quarter, up from 7,822 kgs in the December quarter. The FQ3 kgs sold was 9,160, up from 6,999 kgs in the previous quarter.Both numbers were substantially above prior year levels, but the key is what happens when the current quarter inventory supplies are 150% more than the amount sold in the March quarter.  The average net selling price per gram dipped 20% from last FQ3 to C$6.40 per gram.The company is still promoting the concept of Aurora being EBITDA positive in the June quarter. The stock price would’ve taken a hit, if management walked back from this target, but closing the gap on a C$36.6 million EBITDA loss is an incredible amount and requires strong pricing in the cannabis sector.Aurora didn’t really quantify the need for raising their total projected capacity from 500K kg to 625K kg back in early April. The company is still harping on the potential upside that comes from Ontario opening up additional retail stores and the consumables market opening up in October. The company plans to set aside some of the inventory to build supplies for the vapes and edibles products when the market opens up new revenue streams later this year.TakeawayThe key investor takeaway is that Aurora remains in a precarious position where the company will have a difficult time maintaining previous lofty projections despite the suggestions otherwise with the FQ3 results. With about 1.1 billion shares outstanding and an additional at-the-market offering open for C$400 million worth of shares, the stock has a market value of ~$9 billion with additional dilution on the way.The risk to the downside wasn’t eliminated with this report. If management ever confirms some of the worst fears regarding pricing, mounting losses and wild capacity expansion, the stock will get crushed. For now, Aurora is getting a pass for missing estimates, but this positive outcome won’t always occur.To read more on the nitty gritty of what’s going on in the rising cannabis industry, click here. Read more on ACB: * Aurora Cannabis (ACB) Stock Is Still a Buy, Says Analyst * M&A to Save Aurora Cannabis (ACB) Stock in the End * The Cannabis ‘Magic Bus’ Is About to Leave the Station! Next Stops? Aurora Cannabis (ACB) More recent articles from Smarter Analyst: * Gene Munster: Key Takeaways From Nvidia (NVDA) Earnings * Trade War? Top Analyst Says Alibaba (BABA) Stock Still a Buy * The Green Organic Dutchman (TGODF) Stock -- Not Sinking Exactly, But Not Sailing Anywhere Fast * Is Boeing (BA) Stock a Buy Ahead of FAA Announcement?

  • CNW Group2 days ago

    Canna Cabana Granted Membership into Canadian Franchise Association

    CALGARY , May 17, 2019 /CNW/ - High Tide Inc. ("High Tide" or the "Company") (HITI.CN) (HITIF) (2LY.F), an Alberta -based, retail-focused cannabis corporation enhanced by the manufacturing and wholesale distribution of smoking accessories and cannabis lifestyle products, today announced that Canna Cabana has been granted membership into the Canadian Franchise Association ("CFA").  High Tide is now in possession of a Certificate of Membership for both the Smoker's Corner retail smoking accessories business and the Canna Cabana retail cannabis business, which is unique in Canada .

  • TheStreet.com2 days ago

    Aurora Cannabis Up 2.4%; Tera Tech Off 5.6%: Cannabis Stocks Mixed

    Cannabis stocks were mixed Thursday. Among cannabis stocks tracked by TheStreet, four rose while six fell. Aurora Cannabis shares rose 20.5 cents, or 2.36%, to $8.89. Tera Tech shares fell 4.49 cents, or 5.

  • Benzinga3 days ago

    Aurora Cannabis Exec Says Positive EBITDA Would Be 'Game-Changer'

    Aurora continues to expand its international footprint after establishing a first-mover advantage in most of the 24 countries in which it operates, Singer told "Fast Money" host Melissa Lee. Aurora is evaluating new partnerships with the help of strategic adviser Nelson Peltz, Singer said. Aurora offered the Street a 2019 outlook in January that forces the company to take a "very disciplined" approach to its business, Singer said.

  • The 3 Best Marijuana Stocks to Buy Right Now
    InvestorPlace3 days ago

    The 3 Best Marijuana Stocks to Buy Right Now

    Since their inception, marijuana stocks attracted significant attention. Due to both investment sentiment - and let's face it, raw emotions - the cannabis sector absolutely skyrocketed. But now, the segment is attracting attention for failing to live up to analysts' expectations. Is the honeymoon phase over for weed?Hardly! While cannabis firms have produced some disappointing results during earnings season, that's no reason to abandon them. For one thing, the resurgent U.S.-China trade war is incredibly favorable for marijuana stocks to buy. Prolonged tensions will almost surely cause us economic damage. An easy fix here is to legalize weed and fully open the door to a multi-billion dollar industry.Another reason to stay the course with marijuana stocks to buy is the medicinal-cannabis market. Currently, 33 states have legalized medical marijuana, which is indirectly an indictment against the pharmaceutical industry. As I've argued many times before, pharmaceuticals must take at least some responsibility for the opioid crisis. This story alone has converted many people who have realized the benefits of all-natural treatments.InvestorPlace - Stock Market News, Stock Advice & Trading TipsMoreover, medical marijuana is becoming a popular and potentially profitable exported good. We all know that progressive Europe is receptive to cannabis-based therapies. But more shocking is that conservative Asian countries notorious for their draconian anti-drug policies have demonstrated tolerance. Thailand became the first Southeast Asian country to legalize medical marijuana, while South Korea is the first East Asian country to jump onboard. * Top 7 Dow Jones Stocks of 2019 -- So Far No matter how you look at it, this development strongly benefits the "botanical" industry. Here are the best three marijuana stocks to buy right now: Aurora Cannabis (ACB)Source: Shutterstock Aurora Cannabis (NYSE:ACB) recently issued its earnings results for the first quarter of 2019. Let's just say the print wasn't exactly great for ACB stock. Although Aurora Cannabis' net-revenue haul of 65.2 million CAD exceeded the year-ago quarter's tally by a country mile, it missed analysts' consensus target of 67.6 million CAD.Also a miss was earnings per share. Wall Street expected a loss of 4 cents per share, but Aurora instead delivered a loss of 16 cents. With such a wide gap, conventional wisdom dictates that you should avoid ACB stock.Actually, though, even if Aurora Cannabis hit its metrics with flying colors, I wouldn't pay much attention. Why? Because this is a marathon investment toward an unprecedented sector. As such, you'll find nearer-term noise. Ignore it.The key here is that the management is positioning itself for dominance in the lucrative medical-marijuana market. Its acquisition of Whistler Medical Marijuana indicates that the focus is on quality, not quantity. When weak marijuana stocks get flushed out, ACB will remain standing. Canopy Growth (CGC)Source: Shutterstock Undeniably, a motivating factor to buy shares of Canopy Growth (NYSE:CGC) is the company's international presence. Primarily, it puts up a strong showing in the European mainland. Currently, Canopy is pushing both westward and eastward in the region. However, the ultimate prize for CGC stock and others is the U.S. market.Of course, this is seemingly a pipe dream due to our country's (misguided) Schedule I classification of marijuana. Still, CGC stock jumped mid-April when Canopy announced a contingent offer to buy out Acreage Holdings (OTCMKTS:ACRGF). Canopy will pay $300 million upfront if the U.S. legalizes marijuana.Many botanical advocates argue that Schedule I is a relic of the ignorant and racist past. However, it's still federal law, which means cannabis firms in green-friendly states are still technically at risk. * 7 Stocks to Buy that Lost 10% Last Week But thanks to the U.S.-China trade war, I genuinely believe that full legalization is nearing reality. A prolonged conflict with the world's second-biggest economy will invariably hurt our own fiscal health. That's why the U.S. has to explore marijuana if they insist on playing hardball with China. If so, look for CGC stock to soar. Hexo (HEXO)Source: Shutterstock If you're like most folks who learned about marijuana stocks to buy late in the game, you're probably hesitant on exposing yourself to the top-tier names. After all, we see them splattered on investment headlines all over the internet. If that's you, you might want to check out Hexo (NYSEAMERICAN:HEXO).For starters, Hexo is an understated name. It generates interest, of course, but not nearly as much as the top dogs. I believe that benefits HEXO stock and is partially the reason why shares have steadily made robust gains. Year-to-date, the cannabis firm's equity is up over 113%.That said, HEXO stock has much more upside remaining over the long term. Renowned alcoholic beverage-maker Molson Coors Brewing (NYSE:TAP) has a partnership with Hexo to develop cannabidiol (CBD) infused, non-alcoholic drinks.CBD recently gained mainstream recognition because it offers the cannabis plant's health benefits, but without levering a negative psychoactive effect. In other words, the compound is a perfect gateway for consumers to try other cannabis-based products.This is a partnership that provides multiple natural synergies. Even though it's not quite a household name, you should put Hexo on your list of marijuana stocks to buy.As of this writing, Josh Enomoto did not hold a position in any of the aforementioned securities. More From InvestorPlace * 4 Top American Penny Pot Stocks (Buy Before June 21) * 10 Retirement Stocks That Won't Wilt in a Bear Market * 5 Consumer Stocks Ready to Push Higher * 3 of the Best ETFs to Buy for a Play on Gold Stocks Compare Brokers The post The 3 Best Marijuana Stocks to Buy Right Now appeared first on InvestorPlace.

  • Barrons.com3 days ago

    Aurora Cannabis Is Selling Tons of Marijuana. But It Could Still Have a Rough Road to Profitability.

    Aurora Cannabis thinks it is on the path to profitability after selling nine metric tons of marijuana last quarter. But one analyst isn’t so sure.

  • Aurora Cannabis CCO reveals how Nelson Peltz is guiding company’s U.S. expansion plans
    Yahoo Finance3 days ago

    Aurora Cannabis CCO reveals how Nelson Peltz is guiding company’s U.S. expansion plans

    After notching a 305% increase in net revenue over the same quarter last year, Aurora Cannabis CCO Cam Battley revealed how the company is eyeing profitability and U.S. expansion.

  • Why Aurora Cannabis Stock Could Break Out From Its Trading Range
    InvestorPlace3 days ago

    Why Aurora Cannabis Stock Could Break Out From Its Trading Range

    Since Aurora Cannabis (NYSE: ACB) stock surged in March, ACB stock has been stuck in a narrow trading range between $8.00 and $9.00. Had the markets not sold off due to U.S.-China trade tension worries, Aurora stock would probably not have fallen to $8.38 recently.But it was reported that cannabis sales in Canada had been unchanged over a three-month period. That should not sit well with the owners of ACB stock. * 7 Stocks to Buy that Lost 10% Last Week Cannabis Sales FlatStatistics Canada reported that cannabis sales in January and February were $79 million, flat from September and October 2018. And the 15,000 kilograms of production during that period, down from 22,000 kilograms in the December quarter, should dishearten those owners of ACB stock who expected growth of at least 10%.InvestorPlace - Stock Market News, Stock Advice & Trading TipsAurora Cannabis should get singled out because the company has announced that it will significantly increase its production capacity between now and mid-2020. Aurora expects its production to soon reach 150,000 kg/year, up from 150,000 kg/year in 2018. By mid -2020, it expects its output to surge five-fold to 500,000 kg/year. Low Production CostsAurora has touted its unique cultivation process that it says delivers mass scale, high quality and low production. Yet if cannabis demand is weak in Canada,the owners of ACB stock cannot be sure that global demand for cannabis is growing.In the second quarter, Aurora reported net revenue of $54.2 million. The company's revenue grew 83% quarter-over-quarter. But Aurora stock has an $8 billion market cap, and ACB stock has a price/sales ratio of around 20 times. To retain that high multiple, Aurora must continue reporting strong growth for several quarters. As long as Aurora keeps bringing new product to market, it should have no trouble growing sales and its patient base. (It had a patient base of 73,000 in Q2). $200 Billion Addressable MarketAurora believes the addressable market for medical and global adult-use cannabis is $200 billion. But some may worry that the weak Canadian data indicates that the targeted global market size may not materialize ever or at least for some time. Still, cannabis has the potential to disrupt many markets, including beverages, pharmaceuticals, and tobacco.It is not surprising that Altria (NYSE: MO) invested CAD $2.4 billion (USD $1.78 billion) in Cronos Group (NASDAQ: CRON) last December. That investment lifted the valuations of nearly all cannabis stocks, including ACB stock. So, as cannabis companies report their quarterly earnings, the owners of Aurora stock will look for proof that growth is still in the cards for the cannabis sector. High Expectations for AuroraAurora reported that its revenue had soared 260% in the second quarter, while its average selling price came in at $8.39. But it reported a net loss of CAD $158.3 million (USD $117 million).Though the number of the company's registered medical patients grew 69% to 77,136, the company still lost money. But as Aurora leverages its R&D efforts to develop high-margin products, it will be profitable sooner than most think. That should be a positive catalyst for ACB stock. The Bottom Line on ACB StockAurora Cannabis stock is at a crossroads. Aurora stock may drift lower if markets grow wary of cannabis stocks. Conversely, strong revenue growth could lift Aurora Cannabis stock back to the $9 - $10 range.As of this writing, the author did not hold a position in any of the aforementioned securities. More From InvestorPlace * 4 Top American Penny Pot Stocks (Buy Before June 21) * 10 Stocks to Sell Before They Tank Your Portfolio * Top 7 Dow Jones Stocks of 2019 -- So Far * 5 Low-Priced, High-Potential Tech Stocks to Buy Compare Brokers The post Why Aurora Cannabis Stock Could Break Out From Its Trading Range appeared first on InvestorPlace.

  • Tilray Stock Is Red-Hot, But It’s Fundamentally Flawed
    InvestorPlace3 days ago

    Tilray Stock Is Red-Hot, But It’s Fundamentally Flawed

    Cannabis company Tilray (NASDAQ:TLRY) desperately needed a win with Tuesday's release of its first quarter of 2019 earnings report. Not only is Tilray stock down more than 38% since the end of March, the share price is only one-sixth of its peak value from September of last year.Source: Shutterstock It got the win. Although the net loss per share widened year-over-year, revenue almost tripled. The top line also topped analyst estimates.Perhaps the biggest driver behind Wednesday's initial gain, however, was the discussion of Tilray's growth prospects. Already partnering with beverage giant Anheuser Busch Inbev (NYSE:BUD) to create cannabis-infused drinks, Tilray stock has massive potential. Company CEO Brendan Kennedy fueled those fires, commenting during the conference call about being "inundated" with partnership requests from Fortune 500 companies.InvestorPlace - Stock Market News, Stock Advice & Trading Tips * 10 Retirement Stocks That Won't Wilt in a Bear Market Still, significant challenges remain, spurring a sharp reversal of Wednesday's initial rally in the TLRY stock price. TLRY Earnings RecapTilray wasn't the only name to report last quarter's earnings on Tuesday. Aurora Cannabis (NYSE:ACB) did as well.Tilray was decidedly the better performer of the two, however. As evidence, Tilray stock gained nearly 5% on Tuesday and was up another couple of percentage points early on Wednesday. ACB stock rallied about as well as TLRY stock did on Tuesday but unwound those gains and more on Wednesday.The market celebrated Tilray's sales. The company's top line of $23.0 million, even adjusted downward to $21.5 million to account for excise taxes, still topped the consensus outlook of $20.16 million. The adjusted loss of 27 cents per share of TLRY stock, while much worse than the 7-cent loss per share in the year-ago quarter, essentially met analysts' consensus target.Gross margins improved sequentially, from 20% to 23%. However, they were well off the 50% level seen during Q1 2018, before Canada had legalized recreational marijuana.The volatile margins figure reflects investments made in cultivation facilities and accounting rules about inventory valuations. To meet demand, Tilray is buying marijuana from third-party suppliers. This costs the company more than it would to grow that supply itself. That third-party supply, though, may not be a high-quality leaf.Expenses related to the acquisitions of Manitoba Harvest also took a toll on profitability.When all was said and done though, investors couldn't get over the subtle but telling shift in selling prices. While sales volume more than doubled to 3,012 kilograms, the average selling price fell from $5.94 per gram a year ago to $5.60 per gram last quarter. That slide at least partially reflects the ongoing commoditization of marijuana. Unfortunately, this trend will continue to drive prices lower until only the cost-conscious, high-scale players are left. Perspective Required for TLRY StockTake last quarter's numbers for Tilray stock with a grain of salt, for better or worse. It, like all other marijuana stocks, represents a moving target for several reasons.One of them is the simple fact that the cannabis market in Canada is new. Prior to October, there was no legal adult-use revenue to report.The purchase of Manitoba Harvest also added food sales of $5.6 million to the mix, but only for part of the quarter. It's also arguable that Tilray may be able to better distribute Manitoba's goods better than Manitoba could on its own. If so, it could set the stage for tremendous growth going forward.One area where Tilray is lacking is its international exposure. Overseas sales only totaled $1.8 million last quarter. The right tweaks, however, could readily change that for the better.Still, Tilray boasts some of the primo deals with major names. Aside from the Anheuser Busch partnership, Tilray has inked a supply deal with pharmaceutical giant Novartis (NYSE:NVS). Both could be game-changers once their upsides are fully realized. But it could take several quarters for either large company to decide what they want with their cannabis journey.Selling more marijuana at ever-shrinking prices isn't necessarily a big step in the right direction.Whatever the case, Tilray's most immediate problem is clear. "Our growth internationally and in Canada continue to be limited by lack of supply that we expect to improve over time," explained Tilray Chief Financial Officer Mark Castaneda during the earnings conference call. The company believes it could take up to two more years before supply and demand find an equilibrium. It remains to be seen where the TRLY stock price will stabilize once that equilibrium is met. Looking Ahead for Tilray StockTLRY shares may have initially shot higher in response to first-quarter earnings, but the bounce appears almost pre-planned. It was poised to take shape no matter what due to the sheer severity of the selloff leading into Tuesday's news. Little revealed about the quarter implies much has actually changed since the end of Q4. Everything has just scaled up, including the loss, and the bears were relentless.Those same bears dug in again on Wednesday, recognizing that simply selling marijuana doesn't ensure meaningful or even modest profitability.That's also true of rival marijuana companies, by the way. The entire industry is spending huge sums of money to garner a piece of a market that may not justify the expenditures.Though he was speaking of the decision to establish more capacity rather than arrange for more cultivation, Kennedy's comment about believing "all the hype 18 months ago" rang out alarmingly. He essentially summarized the hype surrounding the cannabis market for the past year-and-a-half.As of this writing, James Brumley did not hold a position in any of the aforementioned securities. You can learn more about James at his site,, or follow him on Twitter, at @jbrumley. More From InvestorPlace * 4 Top American Penny Pot Stocks (Buy Before June 21) * 10 Retirement Stocks That Won't Wilt in a Bear Market * 5 Consumer Stocks Ready to Push Higher * 3 of the Best ETFs to Buy for a Play on Gold Stocks Compare Brokers The post Tilray Stock Is Red-Hot, But It's Fundamentally Flawed appeared first on InvestorPlace.

  • Should You Buy Canopy Growth Stock? 3 Pros, 3 Cons
    InvestorPlace3 days ago

    Should You Buy Canopy Growth Stock? 3 Pros, 3 Cons

    Canopy Growth (NYSE:CGC) just isn't getting as high as it used to. But CGC stock isn't alone. The marijuana stocks have lost a lot of their buzz lately. The sector fund, the Alternative Harvest ETF (NYSEARCA:MJ) has dropped roughly 15% from its recent highs in March. On top of that, its current $33 share price is well off the $45 level where marijuana stocks peaked just before Canada's legalization went into effect last fall.Source: Shutterstock CGC stock has fared better than many of its rivals. But its stock hasn't been able to hit new highs in awhile either, as the $50 price level has been key resistance. With the company making major acquisitions ahead of earnings and short sellers betting the farm against the stock, expect CGC stock to make big moves in coming weeks. CGC Stock ConsAcreage Deal Isn't A Standard Acquisition: Canopy Growth recently announced a deal to purchase Acreage Holdings (OTCMKTS:ACRGF). This deal is a rather odd one for a number of reasons.InvestorPlace - Stock Market News, Stock Advice & Trading Tips * 7 Stocks to Buy that Lost 10% Last Week To start with, the deal is contingent on the U.S. legalizing marijuana federally. The deal is structured with a 90 month (7 and a half years) time limit. It will be terminated if federal legalization doesn't occur within that time frame. As it is, Canopy is taking some risk. That is because it is paying a not insubstantial $300 million upfront for the deal, along with far more than that in CGC stock once the deal closes.Given that the deal could take ages to close, Canopy could be giving up a lot of value with its shares. That will depend on where the share price is in coming years. Additionally, there's a risk that Acreage shareholders will oppose the deal, as Canopy is offering a rather modest premium for the acquisition.CGC Stock Hitting Major Resistance: From a technical analysis standpoint, Canopy Growth stock is starting to get itself into trouble. For the better part of a year now, CGC stock has stopped dead in its tracks every time it reaches near the $50 mark.Canopy Growth stock first hit the $50 level last fall. It spent the better part of September trading around that figure. Shares subsequently dumped all the way to $25. But CGC stock bounced back, hitting $50 again in January. That rally petered out, and shares declined 20%. In April, CGC stock again briefly reclaimed the $50 level but has already dropped back almost 15% since that point. $50 is turning into a major resistance point for Canopy stock. Going forward, bulls need to get the stock to close above $50 before serious trading momentum can get going again.Valuation Is Still Strained: Canopy Growth -- and most of its publicly traded rivals that focus on recreational marijuana -- have yet to deliver compelling earnings. In fact, for many firms, free cash burn has actually gotten worse. Companies keep ramping up their growth expenses without enough revenues to offset those costs just yet.Already, we're starting to see issues on the revenue side. The price of recreational marijuana keeps dropping, sales volumes are flattening out, and producers seemingly have a huge oversupply of marijuana on hand. Canopy still has time to find its way to profitability thanks to the Constellation (NYSE:STZ) cash infusion. But it's burning through that money awfully quickly.Not only are the operations losing money, but it keeps making big purchases like Acreage and the German deal announced earlier this month for close to another $250 million. CGC Stock ProsDeals Could Pay Off Big: While these latest deals certainly come with risk, they could pay off for Canopy. The German deal, acquiring the C3 Cannabinoid Compound Company looks interesting in particular. C3 has developed various products to treat pain in cancer patients, among other uses.C3 already has a healthy $30 million or so in annual revenues. This suggests that Canopy only paid about 8x annual sales for the deal. Compared to many of the deals going off in the hyped-up marijuana space, that's a defensible valuation. $30 million in (presumably fast-growing) annual revenues will be enough to move the needle for Canopy Growth more generally as well.CGC Stock Holding Up Better: Canopy Growth stock is having a mighty difficult time trying to break out above the $50/share level. But at least it is still somewhere near its recent trading highs.Other pot stocks have gotten crushed lately. Cronos (NASDAQ:CRON), Aurora (NYSE:ACB) and Aphria (NASDAQ:APHA) have all fared worse than Canopy. There's a lot of value in being the strongest performing major stock within the industry. When marijuana stocks rally as a group, it may be enough to power CGC stock past that $50 barrier and onward to new all-time highs.Short Squeeze Potential: As I sometimes warn, you generally shouldn't base a whole investment thesis on the potential for a short squeeze. That said, if you are already considering taking a long position, high short interest could be the thing that causes the stock to run in the short term.Canopy Growth's stock has an incredible 75 million shares shorted (on its U.S. listing). That makes up 35% of the float. This is among the highest short ratios you'll find out there for a large widely-traded stock today. Clearly short sellers are betting on Canopy's next earnings report being a dud. That would be in line with what other pot players have produced recently. But if they're wrong, the stock could make a violent move higher. CGC Stock VerdictI don't see this as a great time to get into CGC stock. The firm has outperformed its other marijuana peers recently. But a poor earnings report could drive CGC stock right back down with the rest of the pack. Given how strong the $50 resistance level has been, bears are logically pressing their bets here. * 3 Reasons Not to Sell Canopy Growth Stock If Canopy Growth can deliver a strong earnings report, that would change everything. But until investors see a clearer path to profits and a more stable business trajectory, odds will continue to favor the bears. I'd stick to the sidelines in Canopy stock for the time being.At the time of this writing, Ian Bezek held no positions in any of the aformentioned securities. You can reach him on Twitter at @irbezek. More From InvestorPlace * 4 Top American Penny Pot Stocks (Buy Before June 21) * 10 Retirement Stocks That Won't Wilt in a Bear Market * 5 Consumer Stocks Ready to Push Higher * 3 of the Best ETFs to Buy for a Play on Gold Stocks Compare Brokers The post Should You Buy Canopy Growth Stock? 3 Pros, 3 Cons appeared first on InvestorPlace.

  • Benzinga3 days ago

    Analyst: Aurora Cannabis May Be 'Missing The Boat' In Beverages

    Aurora Cannabis Inc (NYSE: ACB) shares bounced back Wednesday after a mixed fiscal third-quarter earnings report. Carey said Aurora’s third-quarter results were a bit soft compared to his expectations, but investors should expect the company’s numbers to be volatile on a quarter-by-quarter basis in the near term. The most important takeaway from the quarter is Aurora reiterated its fourth-quarter guidance for 25,000 kg of cannabis ready for sale, positive EBITDA and improving margins heading into fiscal 2020.

  • Does Aurora Cannabis Look Attractive after Its Earnings?
    Market Realist3 days ago

    Does Aurora Cannabis Look Attractive after Its Earnings?

    Aurora Cannabis: Analysts' Ratings and Target Price Changed(Continued from Prior Part)Is Aurora Cannabis attractive?Aurora Cannabis (ACB) is one of the top marijuana stocks for investors. The company posted its third-quarter earnings on May 14.